Non-small Cell Lung Cancer Stage I Clinical Trials

2 recruiting

Non-small Cell Lung Cancer Stage I Trials at a Glance

9 actively recruiting trials for non-small cell lung cancer stage i are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Guangdong, Mexico City, and Nanchang. Lead sponsors running non-small cell lung cancer stage i studies include Akeso, Guangzhou Institute of Respiratory Disease, and AIO-Studien-gGmbH.

Browse non-small cell lung cancer stage i trials by phase

Treatments under study

About Non-small Cell Lung Cancer Stage I Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer Stage I? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer Stage I trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer Stage I clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage INon-small Cell Lung Cancer Stage II
Stanford University80 enrolled1 locationNCT04585477
Recruiting
Phase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Stage IIIC
University of California, Davis56 enrolled1 locationNCT07250477
Recruiting
Early Phase 1

[177Lu]Lu-AKIR001 First-in-human Study

Thyroid Gland Anaplastic CarcinomaPoorly Differentiated Thyroid CarcinomaCancer Head and Neck+3 more
Karolinska University Hospital15 enrolled1 locationNCT06639191
Recruiting
Phase 1Phase 2

AK129 Combination Therapy for Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Advanced Solid TumorsColorectal Adenocarcinoma+1 more
Akeso230 enrolled1 locationNCT06943820
Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Non-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIMetastatic Non-small Cell Lung Cancer (NSCLC)
AIO-Studien-gGmbH12,400 enrolled1 locationNCT02622581
Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV
Guangzhou Institute of Respiratory Disease30 enrolled1 locationNCT06310915
Recruiting

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Non-small Cell Lung Cancer Stage IIIA
University Hospital, Toulouse60 enrolled1 locationNCT05732974
Recruiting
Not Applicable

Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane(IMPLANE-0529)

SegmentectomyNon-small Cell Lung Cancer Stage I
The First Affiliated Hospital of Nanchang University272 enrolled1 locationNCT05453721